Vitiligo: Clinical Presentation, Diagnostic Evaluation, Management, and Outcomes – A Case Report

Abstract

Vitiligo is a chronic acquired depigmenting disorder characterized by the selective destruction of melanocytes, resulting in well-demarcated hypopigmented or depigmented macules and patches on the skin. Although not life-threatening, vitiligo significantly impacts psychological well-being and quality of life. The condition is widely considered autoimmune in origin, with genetic, environmental, and oxidative stress factors contributing to its pathogenesis.

We report the case of a 28-year-old female presenting with progressive depigmented patches over the hands and face. Clinical examination and Wood’s lamp evaluation confirmed vitiligo. Laboratory findings suggested an associated autoimmune predisposition. The patient was managed with topical corticosteroids, calcineurin inhibitors, and narrowband ultraviolet B (NB-UVB) therapy, resulting in partial repigmentation and stabilization of disease progression.

This case highlights the importance of early diagnosis, comprehensive evaluation for associated autoimmune conditions, and a multimodal treatment approach in managing vitiligo effectively.

Introduction

Vitiligo is an acquired pigmentary disorder characterized by the loss of functional melanocytes from the epidermis, leading to depigmented skin lesions. It affects approximately 0.5–2% of the global population and can occur at any age, with peak onset in the second and third decades of life.

The condition is classified broadly into segmental and non-segmental types, with non-segmental vitiligo being the most common. The disease course is unpredictable, ranging from slow progression to rapid and widespread depigmentation.

The etiology of vitiligo is multifactorial, involving autoimmune destruction of melanocytes, genetic susceptibility, oxidative stress, and neural mechanisms. It is often associated with other autoimmune disorders such as thyroid disease, diabetes mellitus, and pernicious anemia.

Early diagnosis and intervention are crucial to limit disease progression and improve cosmetic outcomes. Despite advances in therapy, vitiligo remains a therapeutic challenge due to its chronic and relapsing nature.

Case Report

Patient History

A 28-year-old female presented to the dermatology outpatient department with:

• Progressive white patches over the face and hands for 8 months
• Mild itching occasionally at lesion sites
• No pain, scaling, or discharge
• Increasing cosmetic concern and psychological distress

There was no history of trauma, chemical exposure, or prior skin disease. The patient denied any history of similar lesions in childhood.

Medical history revealed hypothyroidism diagnosed 2 years prior, for which she was on regular medication. There was no history of diabetes or other chronic illnesses.

Family history was significant for autoimmune thyroid disease in her mother.

Clinical Examination

General Examination

• Patient conscious and oriented
• Vitals stable
• No pallor, icterus, or lymphadenopathy

Dermatological Examination

• Multiple well-defined depigmented macules and patches
• Distribution: perioral region, periocular area, dorsal hands, and fingers
• Lesions symmetrical in distribution
• No scaling or erythema
• Hair within lesions showed early depigmentation (leukotrichia)

Wood’s Lamp Examination

• Lesions showed bright blue-white fluorescence, confirming depigmentation

Systemic Examination

• No significant abnormalities detected

Clinical Evaluation

Differential Diagnosis

Based on clinical findings, the following were considered:

• Vitiligo (most likely)
• Pityriasis alba
• Tinea versicolor
• Post-inflammatory hypopigmentation
• Chemical leukoderma

The absence of scaling, characteristic distribution, and Wood’s lamp findings strongly supported vitiligo.

Investigations

Laboratory Tests

• Complete blood count: Within normal limits
• Thyroid function tests: Elevated TSH (suggestive of suboptimal control)
• Anti-thyroid peroxidase (anti-TPO) antibodies: Positive
• Fasting blood glucose: Normal
• Vitamin B12 levels: Mildly reduced

Dermatological Tests

• Skin biopsy (if performed):
  • Absence of melanocytes in basal layer
  • Mild lymphocytic infiltration

Imaging

• Not required in this case

Diagnosis

A diagnosis of non-segmental vitiligo associated with autoimmune thyroid disease was established based on clinical features, Wood’s lamp findings, and laboratory investigations.

Management and Outcome

Management Strategy

The treatment approach focused on:

• Arresting disease progression
• Inducing repigmentation
• Addressing associated autoimmune conditions
• Improving psychological well-being

Medical Management

• Topical corticosteroids (mid-potency) for localized lesions
• Topical calcineurin inhibitors (tacrolimus) for facial lesions
• Narrowband UVB (NB-UVB) phototherapy – 2–3 sessions per week

​​​​​​​

• Oral antioxidants (vitamins C and E)

Supportive Measures

• Strict photoprotection with broad-spectrum sunscreen
• Counseling regarding chronic nature of disease
• Psychological support for cosmetic concerns
• Monitoring thyroid function and medication adjustment

Clinical Course

During treatment:

• No new lesions developed after 3 months
• Gradual perifollicular repigmentation observed
• Improvement more prominent on facial lesions compared to hands

Follow-Up

At 1 Month

• Stabilization of lesions
• Reduced psychological distress

At 3 Months

• Early repigmentation noted
• No disease progression

At 6 Months

• Approximately 40–50% repigmentation on face
• Minimal response on acral areas
• Good treatment adherence

Discussion

Pathophysiology

Vitiligo is primarily considered an autoimmune disorder characterized by the destruction of melanocytes. Key mechanisms include:

• Autoimmune hypothesis: Cytotoxic T-cell-mediated melanocyte destruction
• Oxidative stress: Accumulation of reactive oxygen species leading to melanocyte damage
• Genetic factors: Association with specific HLA types
• Neural hypothesis: Neurochemical mediators affecting melanocyte survival

These mechanisms act synergistically, leading to progressive depigmentation.

Etiology

Common contributing factors include:

• Autoimmune diseases (e.g., thyroid disorders)
• Genetic predisposition
• Environmental triggers (chemicals, stress)
• Oxidative stress

In this case, autoimmune thyroid disease likely played a significant role.

Epidemiology

• Affects 0.5–2% of the global population
• Equal prevalence in males and females
• Common onset before 30 years of age
• Higher association with autoimmune disorders

Clinical Manifestations

Early Stage

• Small hypopigmented macules
• Often unnoticed

Progressive Stage

• Well-defined depigmented patches
• Symmetrical distribution
• Common sites: face, hands, elbows, knees

Advanced Stage

• Extensive depigmentation
• Leukotrichia
• Mucosal involvement

Diagnostic Considerations

A structured diagnostic approach includes:

1. Clinical examination
2. Wood’s lamp evaluation
3. Laboratory screening for autoimmune disorders
4. Skin biopsy (in atypical cases)

Wood’s lamp examination is particularly useful in early or subtle lesions.

Treatment Considerations

Management depends on:

• Extent of disease
• Site of lesions
• Disease activity
• Patient preference

Medical Therapy

• First-line treatment for localized disease
• Includes corticosteroids and calcineurin inhibitors

Phototherapy

• NB-UVB is the gold standard for generalized vitiligo
• Promotes melanocyte proliferation and migration

Surgical Therapy

• Considered in stable vitiligo
• Includes melanocyte transplantation

Emerging Therapies

• Janus kinase (JAK) inhibitors
• Targeted immunomodulators

Complications

Vitiligo is not physically disabling but may lead to:

• Psychological distress
• Social stigma
• Reduced quality of life
• Increased risk of sunburn

Prognosis

The prognosis depends on:

• Disease type (segmental vs non-segmental)
• Duration before treatment initiation
• Site of lesions (face responds better than extremities)
• Patient adherence

Early intervention improves outcomes significantly.

Conclusion

Vitiligo is a chronic dermatological condition with significant psychosocial implications. This case highlights the importance of early recognition and a comprehensive evaluation, particularly for associated autoimmune disorders.

A multimodal treatment approach, including topical therapy and phototherapy, can achieve meaningful repigmentation and disease stabilization. However, treatment responses vary depending on lesion location and disease duration.

Long-term management requires patient education, adherence to therapy, and regular follow-up. Addressing psychological aspects is equally critical in improving overall patient outcomes.

With advancements in targeted therapies, the future of vitiligo management holds promise for more effective and sustained repigmentation strategies.

References

1. Taïeb A, Picardo M. Vitiligo. N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/18256395/
2. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. https://pubmed.ncbi.nlm.nih.gov/32171431/
3. Bergqvist C, Ezzedine K. Vitiligo: A review. Dermatology. https://pubmed.ncbi.nlm.nih.gov/30235393/
4. StatPearls. Vitiligo – Clinical Overview. https://www.ncbi.nlm.nih.gov/books/NBK559149/
5. Bolognia JL, Schaffer JV, Cerroni L. Dermatology. https://www.sciencedirect.com/book/9780702062759/dermatology

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors